Teva Unit Targets Celgene Breast Cancer Drug In IP Suit
Teva Pharmaceutical Industries Ltd. unit Cephalon Inc. on Wednesday hit Celgene Corp. with a lawsuit claiming Celgene's breast cancer treatment Abraxane infringes a patent covering formulations of paclitaxel, the drug's active...To view the full article, register now.
Already a subscriber? Click here to view full article